Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - barium selenate - unknown - barium selenate ungrouped active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - barium selenate - unknown - barium selenate ungrouped active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - barium selenate - unknown - barium selenate ungrouped active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - barium selenate - unknown - barium selenate ungrouped active 0.0 - active constituent

New Zealand - English - Ministry for Primary Industries

elanco new zealand - barium selenate - barium selenate 177.48 g/litre - parenteral nutrient/electrolyte

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - selenium as barium selenate - parenteral liquid/solution/suspension - selenium as barium selenate mineral-selenium active 50.0 mg/ml - nutrition & metabolism - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - selenium deficiency | white muscle disease

New Zealand - English - Ministry for Primary Industries

agresearch ltd - barium selenate; hydroxocobalamin hydrochloride - barium selenate 42.6 g/litre; hydroxocobalamin hydrochloride 3 g/litre - parenteral nutrient/electrolyte

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - tagitol v is indicated for use in adult patients for use in computed tomography (ct) colonography as a fecal tagging agent. tagitol v is contraindicated in patients with:    -   known or suspected perforation of the gastrointestinal (gi) tract;    -   known obstruction of the gi tract;    -   high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis;    -   high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation;    -   known hypersensitivity to barium sulfate or any of the excipients of tagitol v. risk summary tagitolv is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary tagitol v is not absorbed systemically by the mother following oral administration and breastfeedin

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar thin honey is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. varibar thin honey is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar thin honey risk summary varibar thin honey is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary varibar thin honey is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the infant to the drug. the efficacy of varibar thin honey in pediatric patients is based on successful opacification of the pharynx during modified barium swallow examinations [see clinical pharmacology (12.1)] . safety and dosing recommendations in pediatric patients are based on clinical experience. varibar thin honey is contraindicated in pediatric patients with trachea-esophageal fistula. [see contraindications (4)]. pediatric patients with a history of asthma or food allergies may be at increased risk for development of hypersensitivity reactions [see warnings and precautions (5.1)]. monitor patients with cystic fibrosis or hirschsprung disease for bowel obstruction after use [see warnings and precautions (5.3)] . clinical studies of varibar thin honey did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar honey is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients 6 months of age and older. varibar honey is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar honey risk summary varibar honey is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary varibar honey is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the infant to the drug. the efficacy of varibar honey in pediatric patients above 6 months of age is based on successful opacification of the pharynx during modified barium swallow examinations [see clinical pharmacology (12.1)] . safety and dosing recommendations in pediatric patients above 6 months of age are based on clinical experience. varibar honey is contraindicated in pediatric patients with trachea-esophageal fistula [see contraindications (4)] . pediatric patients with a history of asthma or food allergies may be at increased risk for development of hypersensitivity reactions [see warnings and precautions (5. 1)] . monitor patients with cystic fibrosis or hirschsprung disease for bowel obstruction after use [see warnings and precautions (5.3)] . clinical studies of varibar honey did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.